Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 76.4%

Gross margin was 76.4% in Q1 FY2026, down 10.3 pp from a year earlier. On a trailing-twelve-month basis it was 80.9%, up 8.2 pp year over year. Over 3 fiscal years it narrowed by 9.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
76.4%-2.4 pp QoQ
Last fiscal yearDec 2025
83.3%+22.7 pp YoY
LTMMar 2026
80.9%+8.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-10.3 pp——
1 year+22.7 pp——
3 years-9.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
83.3%
Year-over-year change
+22.7pp

Gross Margin vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 gross margin of 80.9% is the 5th highest of the 7 companies compared; the peer median is 88.8%.
  • Its year-over-year change of +8.2 pp is the 2nd highest of 6, against a peer median of +3.7 pp.
  • Over three fiscal years its change of -9.0 pp compares with a peer median of -9.3 pp.
AKBA Competitors Peer median
Gross Margin for AKBA and competitors
Company Period LTM level YoY 3-year change
GOSSGossamer Bio, Inc.LTM Mar 202699.6% -0.4 pp—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202592.0% ——
ZVRAZevra Therapeutics, Inc.LTM Mar 202685.5% +6.7 pp-13.3 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 202680.9% +8.2 pp-9.0 pp
PRTAProthena Corporation plcLTM Mar 202646.8% -53.2 pp-38.2 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
Peer median (excluding AKBA) 88.8%+3.7 pp-9.3 pp

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.